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Abstract 
The brain-gut-microbiota axis is increasingly viewed as a novel paradigm in neuroscience 
with the capacity to generate innovative therapies for patients with psychiatric illnesses. 
Psychobiotics, defined as live bacteria which when ingested in adequate amounts confer 
mental health benefits, are increasingly of interest, as pre-clinical trials continue to show 
promising results. Particularly in stress related, anxiety and depressive disorders, there is 
potential for psychobiotics to deliver new therapies. The question of which microbes may 
prove to be the most promising psychobiotic in delivering such therapies at clinical level is of 
great importance. Here we look at the characteristics of psychobiotics, in an attempt to 





CCL- Coping Checklist   
CRP-C Reactive Protein 
CRH-Corticotropin-releasing hormone  
FDA-Food and Drug Administration (US) 
FMT- Faecal Microbiota Transplant  
FOS- Fructo-Oligosaccharides 
GABA- gamma-aminobutyric acid 
GOS- Galacto-Oligosaccharides 
HADS- Hospital Anxiety and Depression Scale   
HMOs- Human Milk Oligosaccharides 
HPA- Hypothalamic-Pituitary-Adrenal axis 
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IL-10- Interleukin 10 
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IL-2-Interleukin 2 
Il-1-Interleukin 1 
IBD- Inflammatory Bowel Disorders  
IGA- Immunoglobulin A 
IGM- Immunoglobulin M 
IND-Investigational New Drug  
MAMPs- Microbe Associated Molecular Patterns 
SCFAs- short chain fatty acids  
TLR -Toll Like Receptor 
TNF-α -Tumour necrosis factor alpha  
UFC- Urinary Free Cortisol  




The brain-gut-microbiota axis consists of several key components, the central nervous 
system, the neuroendocrine system, the neuroimmune system and most importantly the gut 
microbiota. The gut microbiome is composed of all microorganisms and their genomes, in the 
intestinal space. Bacterial concentrations in the gut range from 10
1
-10
3    





 in the colon  (O'Hara and Shanahan 2006).  The complex interaction 
between these components operates in a bi-directional communication network between the 
brain and the gut. Evidence continues to demonstrate that the gut microbiota has significant 
impact on brain function (Stilling, Dinan et al. 2014). Many studies have now demonstrated 
that the gut-brain-microbiota axis contributes to the regulation of brain physiology and 
ultimately behaviour. Various signalling pathways have been suggested, all of which 
demonstrate the link between brain modulation, behaviour and the gut microbiome (Cryan 
and Dinan 2015). 
The term probiotic was first introduced by Metchnikoff in 1908. Probiotics today are defined 
as a live organism that when ingested in adequate amounts, exerts a health benefit  (Dinan 
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and Quigley 2011). However, there is an ongoing need to revise and refine this definition as 
more research is conducted in this area. For example, it has been demonstrated that even dead 
probiotic microorganisms can induce immune reactions when ingested in adequate amounts 
(Dinan, Stanton et al. 2013). Specific probiotics appear to have benefits in particular disease 
states and disorders.  
Prebiotics are indigestible food material, for example oligosaccharides, with selective 
fermentation in the colon, which affects the microbiome by inducing growth, activity or both, 
of one or several bacteria in the microbiome (Roberfroid, Gibson et al. 2010). Prebiotics are 
of interest as several studies have confirmed certain prebiotics can alter the gut microbiota to 
reduce low grade inflammation (Bindels, Delzenne et al. 2015). They can also inhibit the 
growth of pathogenic bacteria. Synbiotics, are described as “mixtures of probiotics and 
prebiotics that beneficially affect the host by improving the survival and implantation of live 
microbial dietary supplements in the gastrointestinal tract, by selectively stimulating the 
growth and/or by activating the metabolism of one or a limited number of health-promoting 
bacteria, thus improving host welfare” (Roberfroid, Gibson et al. 2010). Probiotic 
preparations, containing multiple strains of probiotics have also shown promise in disorders 
such as ulcerative colitis (Wasilewski, Zielinska et al. 2015). These “polybiotic” preparations 
may prove of significant interest in the future development of psychobiotics.  
Since the term Psychobiotics was first introduced in 2012 and defined as “a live organism 
that, when ingested in adequate amounts, produces a health benefit in patients suffering from 
psychiatric illness” (Dinan, Stanton et al. 2013) the search for new and novel therapeutics in 
this area continues. The term psychobiotics has also been expanded to include prebiotics 
(Sarkar, Lehto et al. 2016) and may feasibly confer benefits to both in the patient population 
and the at risk population. Preclinical studies demonstrating the effects of the gut microbiome 
on neuroimmune, neural and hormonal pathways  the suggestion is that the gut microbiota 
can be modulated to treat neuropsychiatric disorders, or at the very least offer adjunctive 
treatment options for these disorders (Cryan and Dinan 2015, Kelly, Clarke et al. 2016).  
Although much has been made of stress related psychiatric disorders, such as depression and 
anxiety, as the exploration of the complex and not fully discovered relationship between the 
brain-gut-microbiota axis continues, there is enormous scope for psychobiotics as 
therapeutics in patients suffering from a wide variety of psychiatric illnesses.  
In the search for psychobiotics, previous studies have focussed on strains of bacteria secreting 
gamma-aminobutyric acid (GABA), tryptophan and short chain fatty acids (SCFAs) or 
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impacting the hypothalamic-pituitary-adrenal axis (HPA) and the inflammatory response 
pathway (Jokela, Hamer et al. 2014). All of these parameters have shown anomalies in stress 
and especially in depression and anxiety disorders.  
How do we identify a beneficial bacterium for neuropsychiatry treatment? How do we set out 
to discover potential new psychobiotics? In this review we discuss the attributes of known 
psychobiotics and the features which provide benefits for hosts. We discuss how these 
benefits are known to affect the brain-gut-microbiota axis. If new putative psychobiotics are 
identified how can we know which might work and allow us to focus only on trials most 
likely to succeed? Here we propose a strategy for the identification of novel psychobiotics. 
 
Brain-gut-microbiota axis abnormalities in depression and related disorders 
Depression is an intricate mood disorder affecting 121 million people worldwide. WHO 
predicts an increase to elevate depressive disorders second only to cardiovascular disease by 
2020 in terms of total disease burden worldwide. Depression is often reoccurring, frequently 
has comorbidity with anxiety and is associated with significant disability worldwide (Kelly, 
Clarke et al. 2016). Depression results in dysregulation of neuroendocrine, neuroimmune, 
neurotransmitter and endocrine functions (Jokela, Hamer et al. 2014). A feature of depression 
which is repeatedly demonstrated is the low-grade inflammatory response observed in this 
patient population (Kelly, Borre et al. 2016). Specific pro-inflammatory biomarkers have 
been identified as being of significance in depression including raised Interleukin (IL)-6, 
Tumour necrosis factor alpha (TNF-α) and C-Reactive Protein (CRP) (O'Brien, Scott et al. 
2004). Such is the impact of certain pro inflammatory cytokines  such as interferon-α, that 
injection with this cytokine is known to induce a depressive episode (McNutt, Liu et al. 
2012). Stress can influence the development of the intestinal barrier and has been linked with 
increased permeability of the gut (Moussaoui, Braniste et al. 2014).  Kelly, Borre et al. (2016) 
have recently shown a significant reduction in microbiota richness and diversity in those 
suffering with depression. Furthermore, transferring the altered gut microbiota to germ-free 
rats induced a depressed-phenotype in these rats. This study suggests that the gut microbiota 
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Genomic identification of psychobiotics 
The most probable method in which to quickly and efficiently identify potential new 
psychobiotics is to fully characterise and analyse individual bacteria currently known to have 
beneficial effects. Individual bacterial strains with various probiotic properties should be 
assessed to unveil the genetic description of those with beneficial phenotypes. This has begun 
in earnest with several recent studies describing whole genomes of various probiotics 
(Arnold, Monteagudo-Mera et al. 2017).   Mapping of the entire gut microbiome  has 
revealed most genes  to be bacterial in origin (Qin, Li et al. 2010). Metagenomic sequencing 
approaches to evaluate the microbiome are useful, however it should be enhanced with 
proteomic and metabolomic  analysis  to determine which microbial genes and proteins are 
expressed in various conditions (Tremaroli and Bäckhed 2012). Such inter-omic analyses 
allows for the investigation and characterisation of the gut microbiota ecosystem. Work to 
date has unveiled various genetic traits, including horizontal gene transfer in some strains of 
Lactobacillus.  (Douillard, Ribbera et al. 2013). Bile resistance, and anti-microbial activity 
have all been identified in  studies in the microbiota (Siezen and van Hylckama Vlieg 2011). 
Further characterisation will allow for a genetic signature to be built in order to identify the 
most appropriate psychobiotics for those suffering with psychiatric conditions. Such an 
approach should hasten discovery and help eliminate unsuitable microbes. 
Studies have highlighted the relationship between the gut microbiome and the mucosal 
proteome (Presley, Ye et al. 2012), indicating that bacterial composition of the microbiome 
may alter the mucosal proteome. McHardy, Goudarzi et al. (2013) demonstrated the 
importance of considering the proteome, metabolome and the genome concurrently. The 
inter-omic play between the microbiome and the mucosa is of upmost importance and should 
not be discarded when considering the complexities of the gut brain axis, and the potential for 
probiotics to alter the axis in various ways. Noecker, Eng et al. (2016) presented a framework 
to take into account all “omic” interactions, in an attempt to evaluate the microbiome at a 
multi-omic, multi-system level, rather than evaluating all aspects individually. This 
framework may allow for better understanding of all factors affecting the microbiome and the 
complex multidimensional interactions at play. It is likely that the genomics of both the host, 
the composites of the microbiome, and the proteomic and metabolomic composition will also 
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Anti-inflammatory action and immune response and its role in Psychobiotic 
identification 
The microbiome interacts with the gut epithelial surface to trigger immune responses and in 
early life plays a key role in shaping the neuroimmune evolution (O'Hara and Shanahan 
2006). In particular Toll Like Receptors (TLRs) which recognise various structural 
components of bacteria can trigger pro-inflammatory responses (McCusker and Kelley 2013). 
An altered gut microbiome in early development can predispose to such varied conditions as 
inflammatory bowel disease (IBD), increased stress reactivity, and predisposition to anxiety 
and depression (Dinan, Stanton et al. 2013). Most probiotics tested have anti-inflammatory 
action which may be beneficial to a multiplicity of states, including such diverse diseases as 
IBD, post-operative states and psychiatric disorders such as anxiety and depression.  Dai, 
Zheng et al. (2013) demonstrated that certain probiotics induce IL-10 anti-inflammatory 
response, and down-regulate a variety of inflammatory drivers including TNF-α and IL-6. 
IL-6 together with IL-2, IL-1 & TNF-α are hallmarks of a depressive disorder and are well 
characterized and readily identifiable in this affective state.  
Probiotic activity has been shown to triggers immune responses stimulating the anti-
inflammatory pathways based on bacteria genera and Microbe Associated Molecular Patterns 
(MAMPs) (Mackey and McFall 2006). MAMPs are thought to trigger such anti-inflammatory 
cytokines as 1L-10 by stimulating pattern-recognition receptors (Chu and Mazmanian 2013). 
In particular, some beneficial bacteria such as Bifidobacteria, appear to prevent TLRs being 
activated and initiating a pro-inflammatory response (Zhou, Lv et al. 2015). Prebiotics and 
probiotics have been shown to interact with TLRs initiating both pro and anti-inflammatory 
responses (Takeda and Akira 2005). There is mounting evidence that prebiotics prevent 
MAMPs triggering immune responses. This mechanism is most likely occurring through 
direct interaction on the gut epithelium with oligosaccharides (Sarkar, Lehto et al. 2016). 
Furthermore, the mere presence of probiotics can have an anti-inflammatory effect. Most are 
gram positive and lack lipopolysaccharide (LPS), reducing pro-inflammatory responses as 
they colonize the gut (Gayathri and Rashmi 2017). Neonatal studies have shown that the 
prebiotic Human Milk Oligosaccharides (HMOs) are particularly adept at inhibiting pro-
inflammatory states (Wickramasinghe, Pacheco et al. 2015). It seems reasonable to assume 
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The Microbiota and Intestinal barrier permeability  
The gut barrier has a pivotal role in defending the body through its epithelium, by 
maintaining pathogens and toxins whilst regulating the absorption of nutrients. The 
microbiota composition has an intricate relationship with the permeability of the epithelial 
membrane, with the microbiota and its metabolites having a role in altering the permeability 
of the membrane (Jakobsson, Rodriguez-Pineiro et al. 2015). Increased permeability of the 
intestinal epithelium has been associated with a pro-inflammatory state (Kelly, Clarke et al. 
2016). In response to an acute stress the colonic paracellular permeability has been shown to 
increase and can be linked to both inflammatory responses and translocation of the gut 
microbiota (Moussaoui, Braniste et al. 2014). Rat pups subjected to early life stress in the 
form of maternal separation, demonstrated altered gut microbiota, increased plasma 
corticosterone and an overall increase in systemic immune response (O'Mahony, Marchesi et 
al. 2009). This may increase susceptibility to pro-inflammatory diseases such as depression 
and anxiety in the future. Increased permeability of the intestinal barrier allows certain gram 
negative bacteria components to translocate from the gut and trigger pro-inflammatory 
pathways (Lucas and Maes 2013). This is the suspected mechanism of action for the 
inflammatory state observed in depression. Higher immunoglobulin (IgA, IgM) mediated 
immune responses to these gram negative bacteria are also observed in depression (Maes, 
Kubera et al. 2013).  
Lactobacillus helveticus R0052 has demonstrated its ability to reduce intestinal permeability 
as a result of a barrier effect (Messaoudi, Lalonde et al. 2011).  Kelly, Borre et al. (2016) 
have shown reduced gut microbiota diversity at phyla level in faecal microbiota transplant 
(FMT) rats from depressed patients. This shows the significant alteration in microbiota in 
neuropsychiatric stress related disorders. The study also showed increased CRP in plasma of 
FMT rats revealing a pro-inflammatory response at systemic level related to the altered 
microbiota. It can be reasonably surmised that the plasma response was secondary to altered 
epithelial permeability as a result of dysbiosis following FMT from depressed subjects. If 
intestinal permeability is compromised the ensuing immune response could trigger an array 
of neuropsychiatric responses. Recent studies have highlighted the role of prebiotics in 
enhancing the microbiota present in the gut. Particular interest is arising in Fructo-
oligosaccharides (FOS) and Galacto-oligosaccharides (GOS). A recent study by Holscher, 
Bode et al. (2017)  has demonstrated that administration of HMOs enhance gut epithelial 
differentiation and maturation.  This study strengthens the theory that oligosaccharides 
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directly affect the epithelium and by preventing a ‘leaky gut’ minimise pro inflammatory 
responses. There is potential to use psychobiotics to target the gut epithelium and to reduce 
permeability in an effort to maintain integrity and reduce immune responses. 
 
Hypothalamic-Pituitary-Adrenal axis (HPA) and the stress response 
The HPA circuit is long recognised as an important regulatory loop between brain and gut.  
Hyper-activation of the HPA has been been identified in various psychological and affective 
states, including depression  anxiety and stress (Flandreau, Ressler et al. 2012). However, the 
question of whether this affective state triggers over-activation of the HPA, or whether 
hyperactivity of the HPA results in the affective state has been the subject of some debate. 
The primary hypothalamic regulatory peptide is Corticotropin-releasing hormone (CRH), in 
response to psychological stress it is released by neurotransmittors such as norepinephrine 
and 5-HT (Dinan and Cryan 2012). Studies evaluating the altered HPA responses in patients 
with both major depression and irritable bowel disease indicate this may be induced by 
increased gut permeability (Dinan and Cryan 2012). The use of germ free animals has 
exposed interesting findings in the role of the microbiota and the development of the HPA. In 
the absence of microbiota in the gut, TLRs have reduced expression in gut epithelia and thus 
they are not present to initiate the immune cascade which results in activation of the HPA 
(Gosselin and Rivest 2008). The stress response in germ free animals results in exaggerated 
release of corticosterone, a response fully reversed by monoassociation with Bifidobacterium 
infantis (Kelly, Clarke et al. 2016). The role of the microbiota in the development of 
appropriate stress responses and the development of the HPA is demonstrated in this study. A 
microbiota demonstrating abilities to reduce a stress response is most clearly showing 
psychobiotic potential. An ongoing question is how best to measure a stress response? Many 
endocrine studies utilise salivary or plasma cortisol sampling, other studies measure various 
cytokine markers. A consensus has yet to be reached.   
 
Short chain fatty acids (SCFAs) and psychobiotic potential 
SCFAs are the metabolites of indigestible macronutrients derived from for example plant 
polysaccharides. The administration of prebiotics increases SCFA production strengthening 
this concept (Psichas, Sleeth et al. 2015). The enzymes to digest such polysaccharides are 
supplied in the human gut by the microbiome (Qin, Li et al. 2010). SCFAs have increasingly 
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been investigated for potential psychobiotic therapy. The SCFAs include butyrate, acetate 
and propionate. Butyrate in particular, has been demonstrated to have antidepressant 
properties in a number of studies. It has the ability to cross the blood brain barrier, and has 
been shown to have numerous neuroprotective abilities, with demonstrated cognitive and 
antidepressant properties (Han, Sung et al. 2014). Further support as to the antidepressant 
effects of butyrate were demonstrated by Moretti, Valvassori et al. (2011) who showed 
reduced stress behaviours and antidepressant effect following systemic butyrate injections in 
rats. This action is in keeping with  butyrate as an epigenetic modulator via its regulation of 
gene expression through inhibition of histone deacetylase  (Stilling, Dinan et al. 2014).   It 
has been noted that SCFAs directly affect the mucosal immune system, can alter the HPA 
axis and through these mechanisms appear to alter the central neurotransmission (Perry, Peng 
et al. 2016). Butyrate’s ability to act as a neuroprotective agent together with its effects on 
memory and cognition is of particular interest given   that loss of cognitive abilities is a long 
recognised and undertreated feature of recurrent and severe depressive disorders. As our 
understanding of SCFAs expands, their potential use as therapeutics becomes more tangible, 
and we foresee a role for SCFAs in the evolution of psychobiotics.  
 
Tryptophan metabolism  
Tryptophan is an essential amino acid that must be ingested in the diet. The brain has limited 
tryptophan storage capacity and consequently a constant supply is required. Certainly reduced 
peripheral levels of tryptophan are associated with a depressive phenotype (Ogawa, Fujii et 
al. 2014).  The brain-gut-microbiota axis and tryptophan metabolism are inherently linked, 
with tryptophan levels and availability influenced directly by the gut microbiota (Desbonnet, 
Garrett et al. 2008).  Bacteria such as Bifidobacteia have been shown to increase peripheral 
tryptophan levels (Desbonnet, Garrett et al. 2008), and  certainly have psychobiotic potential. 
The majority of serotonin is synthesised in the gut by enterochromaffin cells from tryptophan  
and bacteria are thought to play a role in this metabolism (Clarke, Grenham et al. 2013). 
Specific microbiota metabolites have been shown to increase colonic and plasma serotonin 
levels (Kelly, Borre et al. 2016) and in germ free mice, levels of serotonin increase almost 
three fold when colonised by gut microbes (Clarke, Grenham et al. 2013). Bifidobacteria, 
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Diet and mental illness 
Diet in a healthy adult is the main determinant of gut microbiota composition. The 
association between diet and psychiatric disorders, particularly depression and anxiety has 
long been suggested and gut microbes may be the important linking factor. Association 
between the Mediterranean diet and reduction in depression is well established. The 
Mediterranean diet is defined as being high in plant foods (fruit, vegetables, breads, cereals, 
potatoes, beans, nuts, and seeds), fresh fruit, olive oil, moderate amounts of dairy products 
(cheese and yogurt), and fish and poultry, zero to four eggs consumed weekly, red meat 
consumed in low amounts, and wine consumed in low to moderate amounts, traditionally 
with meals. Even moderate adherence to the Mediterranean diet results in reduced risk of 
depression (Psaltopoulou, Sergentanis et al. 2013). Other studies have demonstrated that a 
more “Western diet”, defined as a diet high in processed or fried foods, refined grains, sugary 
products, and beer, are associated with higher reported levels of anxiety and depression in 
women (Jacka, Pasco et al. 2010).  Analysis of the microbiota in those on a Mediterranean 
diet may help identify bacterial strains with psychobiotic activity. 
 
 
What behavioural studies in rodents help to identify psychobiotics? 
A number of well validated rodent behavioural tests are used to assess the effects of altering 
gut microbiota on such mental states. The rodent response in such tests allows for inference 
of effects from specific bacteria. In approach-orientation, time spent exploring new 
environments is a key behavioural feature, as it is crucial for the rodent to do so in order to 
adapt to novel and changing environments. Stress and anxiety are shown to significantly 
reduce exploration behaviours. The forced swim test in rodents, is based on progressive 
immobility displayed by the rodent when forced to swim in a container of water. Immobility 
in the forced swim test has long been associated with increased anxiety and depressive 
behaviours in rodents. The test has frequently been used to identify the antidepressant 
potential of drugs, and now psychobiotics.  
Germ free mice demonstrate reduced anxiety by showing more exploratory behaviours in 
approach orientation tests (Diaz Heijtz, Wang et al. 2011). However once germ free mice are 
exposed to stress they exhibit elevated and exaggerated glucocorticoid responses, and 
reduced exploratory behaviours (Desbonnet, Clarke et al. 2015). Proving beneficial in 
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examining how the gut microbiota may alter rodents behavioural phenotype is the use of 
faecal transfer of the microbiota of interest to germ free rodents. Bercik, Denou et al. (2011) 
have shown that transferring the microbiota from stress-sensitive mice strains to non-anxious 
mice strains, can alter phenotype and reduce exploratory behaviours inferring increased 
anxiety in the recipient mice. 
Testing of potential psychobiotics using rodent behavioural tests is an important step in 
psychobiotic identification. 
 
Prebiotics, “Polybiotics” & Synbiotics as Psychobiotics 
Prebiotics have been defined  as “a non-digestible food ingredient that beneficially affects the 
host by selectively stimulating the growth and/or activity of one or a limited number of 
bacteria in the colon” (Roberfroid, Gibson et al. 2010). Studies have shown prebiotics may 
have an ability to survive for extended periods in the gut, and one study has shown potential 
to promote longstanding benefits up to a year after administration (Oliveros, Ramirez et al. 
2016). This makes prebiotics increasingly attractive as vehicles for modulating the brain-gut-
microbiota axis.  
The probiotic “live microorganisms that, when administered in adequate amounts, confer a 
health benefit on the host” has a transient modulating effect on the gut microbiota. Multiple 
studies show improved functionality which is quickly lost on withdrawal of the probiotic. For 
example, significantly there is reduced anxiety in mice within  1 week of probiotic treatment, 
with no effect observed at 3 weeks post treatment (Matthews and Jenks 2013).  Patients with 
IBD report an emergence of symptoms within days of discontinuation of probiotics.  
A modified GOS (Bimuno-GOS or B-GOS) and FOS has been shown to have 
neuroprotective properties in animal models. With administration of B-GOS showing clear 
evidence of increasing availability of brain derived neurotrophic factor (BDNF) in the 
hippocampal region (Savignac, Tramullas et al. 2015). There is also evidence of increased 
cognitive abilities particularly in the area of memory observed following increased BDNF 
levels (Williams, Chen et al. 2016). Other studies involving B-GOS and FOS have 
established that the administration of B-GOS significantly lowers the salivary cortisol 
response (Schmidt, Cowen et al. 2015) . B-GOS reduces anxiety and expected cytokine stress 
responses in B-GOS fed mice. This study indicates that B-GOS exerts its anxiolytic effect 
through modulation of IL-1β and 5-HT2A (Savignac, Tramullas et al. 2015). Human studies 
 
 
This article is protected by copyright. All rights reserved. 
have also demonstrated benefits from B-GOS in emotional processing (Schmidt, Cowen et al. 
2015).  All of which further supports the potential role of oligosaccharides and in particular 
B-GOS as a potential psychobiotics, whether alone or as adjunctive therapy in affective and 
anxiety disorders. 
Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 demonstrate anti-
inflammatory properties on intestinal epithelial cells (Messaoudi, Lalonde et al. 2011) and 
poly-psychobiotics  administration of Lactobacillus helveticus R0052 and Bifidobacterium 
longum R0175 concurrently have shown good evidence of reducing depressive behaviours in 
mice post Myocardial Infarction (Arseneault-Breard, Rondeau et al. 2012), while showing the 
ability to reduce anxiety levels in healthy volunteers and 24 hour urinary cortisol output. The 
recurrent difficulties with these studies is that probiotics, whether in multiple strain or single 
strain, are transient and do not colonise the gut permanently.  
Increasingly of interest is synbiotics, a prebiotic co-administered with probiotic. Some studies 
have demonstrated good use of synbiotics in IBD  (Wasilewski, Zielinska et al. 2015) with 
significant reductions observed and maintained in TNF-alpha for up to 6 months post 
treatment.  
VSL #3 is a probiotic preparation or formula composed of eight live freeze-dried bacterial 
species that are normal components of the human gastrointestinal microflora, including four 
strains of lactobacilli (Lactobacillus casei, L. plantarum, L. acidophilus and L. 
delbrueckii subsp. bulgaricus), three strains of bifidobacteria (Bifidobacterium longum, B. 
breve and B. infantis) and Streptococcus salivarius subsp. thermophilus. VSL #3 has 
demonstrated good results for patients in conditions such as ulcerative colitis and irritable 
bowel syndrome (Wasilewski, Zielinska et al. 2015). This probiotic preparation could be 
considered a “polybiotic” and there is the potential to co-administer probiotic formula in the 
search for psychobiotic therapies. The potential for synbiotics, the amalgamation of pro and 
prebiotics, is increasingly of interest in the search for psychobiotics. So far no major studies 
of synbiotics in humans with mental health disorders have been reported. 
There may too be a role for multi-strain probiotics or cocktails for pro and prebiotics to be 
administered in order to confer less transient and more long term benefits.  There is as yet no 
consensus on whether psychobiotic potential is achieved best with a single strain probiotic, a 
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Discussion 
Determining the preclinical markers that best identify psychobiotics that will benefit patients 
with depression and related disorders is a major challenge.  Only by adequate preclinical 
evaluation coupled with good clinical studies will effective algorithms emerge for identifying 
likely psychobiotics. Not all prebiotic, probiotic or synbiotics will have psychobiotic 
potential, and not all that show preclinical promise will be suitable for further development.   
In investigating and developing psychobiotics it is important to focus on those strains that 
have shown effects on behaviour, gut permeability, are neuroactive, and reduce pro 
inflammatory and stress responses in pre-clinical studies. Even this strategy will have 
difficulties however. For example, Lactobacillus rhamnosus strain JB-1, demonstrated an 
ability to  reduce stress-related behaviour, corticosterone release and alter central expression 
of GABA receptors in an anxious mouse strain (Bravo, Forsythe et al. 2011). Lactobacillus 
rhamnosus was therefore predicted to have good potential as a psychobiotic. However, these 
promising pre-clinical findings, did not translate in healthy male volunteers. There was no 
difference between  Lactobacillus rhamnosus and placebo in an 8 week trial in healthy 
volunteers with a crossover design (Kelly, Allen et al. 2017). This highlights the need for 
preclinical trials to be moved quickly forward to interventional studies in populations with 
anxiety, depression and stress related disorders.   
Other more promising progress has been made. A double-blind, placebo-controlled, 
randomized study was conducted on volunteers with symptoms of stress. Subjects received a 
probiotic (Probio-Stick; Lallemand SAS, Saint-Simon, France) containing Lactobacillus 
helveticus R0052 and Bifidobacterium longum R00175 (3 × 10
9
colony-forming units per 
sachet stick) or an identical placebo without probiotics for a 3-week period. Though this 
study showed reductions in stress related abdominal discomfort, it did not have any effect on 
other symptoms of stress, for example sleep. A further follow up double blind randomised 
control study by   of the same preparation delivered for 4 weeks, showed significantly 
reduced stress levels in volunteers as recorded using various stress measurement tools 
(Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale 
(HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and a 24h urinary free 
cortisol (UFC) collection. In 2016, on foot of both studies Lallemands’s Probio’Stick® 
(Lactobacillus helveticus R0052 and Bifidobacterium longum Rossell®-175 in a stick 
presentation) has been accepted by the Canadian Health Authorities for benefits in the area of 
stress, anxiety and mood. 
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Personalised psychobiotics may have a role in the future. Many researchers have now 
recognised that though identical bacterial species colonise the human gut, varying genetics, 
life experiences and exposures alter the composition of the gut microbiota. This may affect 
the clinical presentation of the individual in various affective or stress related disorders. This 
will alter the best “prescribed” probiotic required to address the individual’s anxiety or 
depression.  Presently however, the priority lies in identifying generic psychobiotics 
beneficial to many patients, prior to individualisation becoming a reality.  
As research continues the more fundamental the gut microbiota appears to be in affecting the 
entire system, at almost all conceivable levels. In order to confer the most benefit from 
potential psychobiotics and develop future therapeutics continuing to evaluate the manner in 
which they are altering the gut microbiota is of upmost importance. The ability of potential 
psychobiotics to act on the areas outlined here will allow researchers to target trials on 
probiotics, probiotic formulations, prebiotics or synbiotics showing preclinical promise and 
avoid wasting valuable cost and time on unlikely candidates. A targeted and predictive 
approach may, hopefully, allow the development of psychobiotics in a timely fashion.     
 
Nomenclature of targets and ligands 
Key protein targets in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY(Southan, Sharman et al. 2015), and are permanently archived 




The authors are supported in part by Science Foundation Ireland in the form of a centre grant 
(Alimentary Pharmabiotic Centre Grant Number SFI/12/RC/2273); by the Health Research 
Board of Ireland (Grant Numbers HRA_POR/2011/23 and HRA_POR/2012/32) and received 
funding from the European Community’s Seventh Framework Programme Grant MyNewGut 
under Grant Agreement No. FP7/2007-2013. The Centre has conducted studies in 
collaboration with several companies including GSK, Pfizer, Cremo, Suntory, Wyeth and 
Mead Johnson.  
 
 
This article is protected by copyright. All rights reserved. 
References 
1. Alexander, S. P. H., D. Fabbro, E. Kelly, N. V. Marrion, J. A. Peters, E. Faccenda, S. D. Harding, 
A. J. Pawson, J. L. Sharman, C. Southan, J. A. Davies and C. Collaborators (2017). "THE 
CONCISE GUIDE TO PHARMACOLOGY 2017/18: Catalytic receptors." British Journal of 
Pharmacology 174: S225-S271. 
2. Arnold, J. W., A. Monteagudo-Mera, E. Altermann, M. B. Cadenas, A. L. Thompson and M. A. 
Azcarate-Peril (2017). "Genome Sequences of Potential Probiotic Lactobacillus rhamnosus 
Isolates from Human Infants." Genome announcements 5(14): e00107-00117. 
3. Arseneault-Breard, J., I. Rondeau, K. Gilbert, S. A. Girard, T. A. Tompkins, R. Godbout and G. 
Rousseau (2012). "Combination of Lactobacillus helveticus R0052 and Bifidobacterium 
longum R0175 reduces post-myocardial infarction depression symptoms and restores 
intestinal permeability in a rat model." Br J Nutr 107(12): 1793-1799. 
4. Bercik, P., E. Denou, J. Collins, W. Jackson, J. Lu, J. Jury, Y. Deng, P. Blennerhassett, J. Macri, 
K. D. McCoy, E. F. Verdu and S. M. Collins (2011). "The Intestinal microbiota affect central 
levels of brain-derived neurotropic factor and behavior in mice." Gastroenterology 141(2): 
599-609.e593. 
5. Bindels, L. B., N. M. Delzenne, P. D. Cani and J. Walter (2015). "Towards a more 
comprehensive concept for prebiotics." Nat Rev Gastroenterol Hepatol. 
6. Bravo, J. A., P. Forsythe, M. V. Chew, E. Escaravage, H. M. Savignac, T. G. Dinan, J. 
Bienenstock and J. F. Cryan (2011). "Ingestion of Lactobacillus strain regulates emotional 
behavior and central GABA receptor expression in a mouse via the vagus nerve." Proc Natl 
Acad Sci U S A 108(38): 16050-16055. 
7. Chu, H. and S. K. Mazmanian (2013). "Innate immune recognition of the microbiota 
promotes host-microbial symbiosis." Nature immunology 14(7): 668-675. 
8. Clarke, G., S. Grenham, P. Scully, P. Fitzgerald, R. D. Moloney, F. Shanahan, T. G. Dinan and J. 
F. Cryan (2013). "The microbiome-gut-brain axis during early life regulates the hippocampal 
serotonergic system in a sex-dependent manner." Mol Psychiatry 18(6): 666-673. 
9. Cryan, J. F. and T. G. Dinan (2015). "Gut microbiota: Microbiota and neuroimmune signalling-
Metchnikoff to microglia." Nat Rev Gastroenterol Hepatol. 
10. Dai, C., C.-Q. Zheng, F.-j. Meng, Z. Zhou, L.-x. Sang and M. Jiang (2013). "VSL# 3 probiotics 
exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-
induced colitis." Molecular and Cellular Biochemistry 374(1-2): 1-11. 
11. Desbonnet, L., G. Clarke, A. Traplin, O. O'Sullivan, F. Crispie, R. D. Moloney, P. D. Cotter, T. G. 
Dinan and J. F. Cryan (2015). "Gut microbiota depletion from early adolescence in mice: 
Implications for brain and behaviour." Brain Behav Immun 48: 165-173. 
12. Desbonnet, L., L. Garrett, G. Clarke, J. Bienenstock and T. G. Dinan (2008). "The probiotic 
Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat." J 
Psychiatr Res 43(2): 164-174. 
13. Diaz Heijtz, R., S. Wang, F. Anuar, Y. Qian, B. Bjorkholm, A. Samuelsson, M. L. Hibberd, H. 
Forssberg and S. Pettersson (2011). "Normal gut microbiota modulates brain development 
and behavior." Proc Natl Acad Sci U S A 108(21282636): 3047-3052. 
14. Dinan, T. G. and J. F. Cryan (2012). "Regulation of the stress response by the gut microbiota: 
implications for psychoneuroendocrinology." Psychoneuroendocrinology 37(9): 1369-1378. 
15. Dinan, T. G. and E. M. Quigley (2011). "Probiotics in the treatment of depression: science or 
science fiction?" Australian & New Zealand Journal of Psychiatry 45(12): 1023-1025. 
16. Dinan, T. G., C. Stanton and J. F. Cryan (2013). "Psychobiotics: A Novel Class of Psychotropic." 
Biol Psychiatry. 
17. Douillard, F. P., A. Ribbera, R. Kant, T. E. Pietilä, H. M. Järvinen, M. Messing, C. L. Randazzo, L. 
Paulin, P. Laine and J. Ritari (2013). "Comparative genomic and functional analysis of 100 
 
 
This article is protected by copyright. All rights reserved. 
Lactobacillus rhamnosus strains and their comparison with strain GG." PLoS Genet 9(8): 
e1003683. 
18. Flandreau, E. I., K. J. Ressler, M. J. Owens and C. B. Nemeroff (2012). "Chronic 
overexpression of corticotropin-releasing factor from the central amygdala produces HPA 
axis hyperactivity and behavioral anxiety associated with gene-expression changes in the 
hippocampus and paraventricular nucleus of the hypothalamus." Psychoneuroendocrinology 
37(1): 27-38. 
19. Gayathri, D. and B. Rashmi (2017). "Mechanism of Development of Depression and 
Probiotics as Adjuvant Therapy for its Prevention and Management." Mental Health & 
Prevention. 
20. Gosselin, D. and S. Rivest (2008). "MyD88 signaling in brain endothelial cells is essential for 
the neuronal activity and glucocorticoid release during systemic inflammation." Molecular 
psychiatry 13(5): 480. 
21. Han, A., Y.-B. Sung, S.-Y. Chung and M.-S. Kwon (2014). "Possible additional antidepressant-
like mechanism of sodium butyrate: targeting the hippocampus." Neuropharmacology 81: 
292-302. 
22. Holscher, H. D., L. Bode and K. A. Tappenden (2017). "Human milk oligosaccharides influence 
intestinal epithelial cell maturation in vitro." Journal of pediatric gastroenterology and 
nutrition 64(2): 296-301. 
23. Jacka, F. N., J. A. Pasco, A. Mykletun, L. J. Williams, A. M. Hodge, S. L. O'Reilly, G. C. 
Nicholson, M. A. Kotowicz and M. Berk (2010). "Association of Western and traditional diets 
with depression and anxiety in women." Am J Psychiatry 167(3): 305-311. 
24. Jakobsson, H. E., A. M. Rodriguez-Pineiro, A. Schutte, A. Ermund, P. Boysen, M. Bemark, F. 
Sommer, F. Backhed, G. C. Hansson and M. E. Johansson (2015). "The composition of the gut 
microbiota shapes the colon mucus barrier." EMBO Rep 16(2): 164-177. 
25. Jokela, M., M. Hamer, A. Singh-Manoux, G. D. Batty and M. Kivimaki (2014). "Association of 
metabolically healthy obesity with depressive symptoms: pooled analysis of eight studies." 
Mol Psychiatry 19(8): 910-914. 
26. Kelly, J. R., A. P. Allen, A. Temko, W. Hutch, P. J. Kennedy, N. Farid, E. Murphy, G. Boylan, J. 
Bienenstock, J. F. Cryan, G. Clarke and T. G. Dinan (2017). "Lost in translation? The potential 
psychobiotic Lactobacillus rhamnosus (JB-1) fails to modulate stress or cognitive 
performance in healthy male subjects." Brain Behav Immun 61: 50-59. 
27. Kelly, J. R., Y. Borre, O. B. C, E. Patterson, S. El Aidy, J. Deane, P. J. Kennedy, S. Beers, K. Scott, 
G. Moloney, A. E. Hoban, L. Scott, P. Fitzgerald, P. Ross, C. Stanton, G. Clarke, J. F. Cryan and 
T. G. Dinan (2016). "Transferring the blues: Depression-associated gut microbiota induces 
neurobehavioural changes in the rat." J Psychiatr Res 82: 109-118. 
28. Kelly, J. R., G. Clarke, J. F. Cryan and T. G. Dinan (2016). "Brain-gut-microbiota axis: 
challenges for translation in psychiatry." Ann Epidemiol. 
29. Lucas, K. and M. Maes (2013). "Role of the Toll Like receptor (TLR) radical cycle in chronic 
inflammation: possible treatments targeting the TLR4 pathway." Mol Neurobiol 48(1): 190-
204. 
30. Mackey, D. and A. J. McFall (2006). "MAMPs and MIMPs: proposed classifications for 
inducers of innate immunity." Molecular microbiology 61(6): 1365-1371. 
31. Maes, M., M. Kubera, J. C. Leunis, M. Berk, M. Geffard and E. Bosmans (2013). "In 
depression, bacterial translocation may drive inflammatory responses, oxidative and 
nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged 
neoepitopes." Acta Psychiatr Scand 127(5): 344-354. 
32. Matthews, D. M. and S. M. Jenks (2013). "Ingestion of Mycobacterium vaccae decreases 
anxiety-related behavior and improves learning in mice." Behavioural processes 96: 27-35. 
33. McCusker, R. H. and K. W. Kelley (2013). "Immune-neural connections: how the immune 
system's response to infectious agents influences behavior." J Exp Biol 216(Pt 1): 84-98. 
 
 
This article is protected by copyright. All rights reserved. 
34. McHardy, I. H., M. Goudarzi, M. Tong, P. M. Ruegger, E. Schwager, J. R. Weger, T. G. Graeber, 
J. L. Sonnenburg, S. Horvath and C. Huttenhower (2013). "Integrative analysis of the 
microbiome and metabolome of the human intestinal mucosal surface reveals exquisite 
inter-relationships." Microbiome 1(1): 17. 
35. McNutt, M. D., S. Liu, A. Manatunga, E. B. Royster, C. L. Raison, B. J. Woolwine, M. F. 
Demetrashvili, A. H. Miller and D. L. Musselman (2012). "Neurobehavioral effects of 
interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to 
paroxetine." Neuropsychopharmacology 37(6): 1444-1454. 
36. Messaoudi, M., R. Lalonde, N. Violle, H. Javelot, D. Desor, A. Nejdi, J. F. Bisson, C. Rougeot, 
M. Pichelin, M. Cazaubiel and J. M. Cazaubiel (2011). "Assessment of psychotropic-like 
properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium 
longum R0175) in rats and human subjects." Br J Nutr 105(5): 755-764. 
37. Moretti, M., S. S. Valvassori, R. B. Varela, C. L. Ferreira, N. Rochi, J. Benedet, G. Scaini, F. 
Kapczinski, E. L. Streck and A. I. Zugno (2011). "Behavioral and neurochemical effects of 
sodium butyrate in an animal model of mania." Behavioural pharmacology 22(8): 766-772. 
38. Moussaoui, N., V. Braniste, A. Ait-Belgnaoui, M. Gabanou, S. Sekkal, M. Olier, V. Theodorou, 
P. G. Martin and E. Houdeau (2014). "Changes in intestinal glucocorticoid sensitivity in early 
life shape the risk of epithelial barrier defect in maternal-deprived rats." PLoS One 9(2): 
e88382. 
39. Noecker, C., A. Eng, S. Srinivasan, C. M. Theriot, V. B. Young, J. K. Jansson, D. N. Fredricks and 
E. Borenstein (2016). "Metabolic model-based integration of microbiome taxonomic and 
metabolomic profiles elucidates mechanistic links between ecological and metabolic 
variation." mSystems 1(1): e00013-00015. 
40. O'Brien, S. M., L. V. Scott and T. G. Dinan (2004). "Cytokines: abnormalities in major 
depression and implications for pharmacological treatment." Human Psychopharmacology: 
clinical and experimental 19(6): 397-403. 
41. O'Hara, A. M. and F. Shanahan (2006). "The gut flora as a forgotten organ." EMBO Rep 7(7): 
688-693. 
42. O'Mahony, S. M., J. R. Marchesi, P. Scully, C. Codling, A.-M. Ceolho, E. M. Quigley, J. F. Cryan 
and T. G. Dinan (2009). "Early life stress alters behavior, immunity, and microbiota in rats: 
implications for irritable bowel syndrome and psychiatric illnesses." Biological psychiatry 
65(3): 263-267. 
43. Ogawa, S., T. Fujii, N. Koga, H. Hori, T. Teraishi, K. Hattori, T. Noda, T. Higuchi, N. Motohashi 
and H. Kunugi (2014). "Plasma L-tryptophan concentration in major depressive disorder: 
new data and meta-analysis." J Clin Psychiatry 75(9): e906-e915. 
44. Oliveros, E., M. Ramirez, E. Vazquez, A. Barranco, A. Gruart, J. M. Delgado-Garcia, R. Buck, R. 
Rueda and M. J. Martin (2016). "Oral supplementation of 2′-fucosyllactose during lactation 
improves memory and learning in rats." The Journal of nutritional biochemistry 31: 20-27. 
45. Perry, R. J., L. Peng, N. A. Barry, G. W. Cline, D. Zhang, R. L. Cardone, K. F. Petersen, R. G. 
Kibbey, A. L. Goodman and G. I. Shulman (2016). "Acetate mediates a microbiome–brain–β-
cell axis to promote metabolic syndrome." Nature 534(7606): 213-217. 
46. Presley, L. L., J. Ye, X. Li, J. LeBlanc, Z. Zhang, P. M. Ruegger, J. Allard, D. McGovern, A. Ippoliti 
and B. Roth (2012). "Host–microbe relationships in inflammatory bowel disease detected by 
bacterial and metaproteomic analysis of the mucosal–luminal interface." Inflammatory 
bowel diseases 18(3): 409-417. 
47. Psaltopoulou, T., T. N. Sergentanis, D. B. Panagiotakos, I. N. Sergentanis, R. Kosti and N. 
Scarmeas (2013). "Mediterranean diet, stroke, cognitive impairment, and depression: a 
meta-analysis." Ann Neurol 74. 
48. Psichas, A., M. Sleeth, K. Murphy, L. Brooks, G. Bewick, A. Hanyaloglu, M. Ghatei, S. Bloom 
and G. Frost (2015). "The short chain fatty acid propionate stimulates GLP-1 and PYY 
 
 
This article is protected by copyright. All rights reserved. 
secretion via free fatty acid receptor 2 in rodents." International journal of obesity 39(3): 
424-429. 
49. Qin, J., R. Li, J. Raes, M. Arumugam, K. S. Burgdorf and C. Manichanh (2010). "A human gut 
microbial gene catalogue established by metagenomic sequencing." Nature 464: 59-65. 
50. Roberfroid, M., G. R. Gibson, L. Hoyles, A. L. McCartney, R. Rastall, I. Rowland, D. Wolvers, B. 
Watzl, H. Szajewska, B. Stahl, F. Guarner, F. Respondek, K. Whelan, V. Coxam, M. J. Davicco, 
L. Leotoing, Y. Wittrant, N. M. Delzenne, P. D. Cani, A. M. Neyrinck and A. Meheust (2010). 
"Prebiotic effects: metabolic and health benefits." Br J Nutr 104 Suppl 2: S1-63. 
51. Sarkar, A., S. M. Lehto, S. Harty, T. G. Dinan, J. F. Cryan and P. W. J. Burnet (2016). 
"Psychobiotics and the Manipulation of Bacteria–Gut–Brain Signals." Trends in 
Neurosciences 39(11): 763-781. 
52. Savignac, H. M., M. Tramullas, B. Kiely, T. G. Dinan and J. F. Cryan (2015). "Bifidobacteria 
modulate cognitive processes in an anxious mouse strain." Behav Brain Res 287: 59-72. 
53. Schmidt, K., P. J. Cowen, C. J. Harmer, G. Tzortzis, S. Errington and P. W. Burnet (2015). 
"Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy 
volunteers." Psychopharmacology 232(10): 1793-1801. 
54. Siezen, R. J. and J. E. van Hylckama Vlieg (2011). "Genomic diversity and versatility of 
Lactobacillus plantarum, a natural metabolic engineer." Microbial cell factories 10(1): S3. 
55. Southan, C., J. L. Sharman, H. E. Benson, E. Faccenda, A. J. Pawson, S. P. Alexander, O. P. 
Buneman, A. P. Davenport, J. C. McGrath and J. A. Peters (2015). "The IUPHAR/BPS Guide to 
PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein 
targets and 6000 ligands." Nucleic acids research 44(D1): D1054-D1068. 
56. Stilling, R. M., T. G. Dinan and J. F. Cryan (2014). "Microbial genes, brain & behaviour - 
epigenetic regulation of the gut-brain axis." Genes Brain Behav 13(1): 69-86. 
57. Takeda, K. and S. Akira (2005). "Toll-like receptors in innate immunity." Int Immunol 17(1): 1-
14. 
58. Tremaroli, V. and F. Bäckhed (2012). "Functional interactions between the gut microbiota 
and host metabolism." Nature 489(7415): 242. 
59. Wasilewski, A., M. Zielinska, M. Storr and J. Fichna (2015). "Beneficial effects of probiotics, 
prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease." Inflammatory 
bowel diseases 21(7): 1674-1682. 
60. Wickramasinghe, S., A. R. Pacheco, D. G. Lemay and D. A. Mills (2015). "Bifidobacteria grown 
on human milk oligosaccharides downregulate the expression of inflammation-related genes 
in Caco-2 cells." BMC microbiology 15(1): 172. 
61. Williams, S., L. Chen, H. M. Savignac, G. Tzortzis, D. C. Anthony and P. W. Burnet (2016). 
"Neonatal prebiotic (BGOS) supplementation increases the levels of synaptophysin, 
GluN2A‐subunits and BDNF proteins in the adult rat hippocampus." Synapse 70(3): 121-124. 
62. Zhou, W., H. Lv, M. Li, H. Su, L. Huang, J. Li and W. Yuan (2015). "Protective effects of 
bifidobacteria on intestines in newborn rats with necrotizing enterocolitis and its regulation 





This article is protected by copyright. All rights reserved. 
 
 
Figure 1. The search for Psychobiotics. This illustrates the potential pathway for psychobiotic 
identification. The first step in the process is genome sequencing and comparison with strains know to 
have psychobiotic potential. Determining the potential to generate short chain fatty acids and 
tryptophan is a fundamental step in the process, as is the ability to demonstrate anti-inflammatory 
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Figure 2. The gut brain axis. Comparison between a healthy gut brain system and an abnormal system. 
In negative affective states such as stress anxiety or depression, pro-inflammatory markers increase, 
gut microbiota and gut permeability is altered and the gut brain axis is in a state of dysbosis. 
